Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...
ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...
Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific
Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...
Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy
California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...
Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection
Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET...
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...
Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China
US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced...
Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...
Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...
MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...
Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment
China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...
Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease
China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...
Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment
Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...
Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies
Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...
Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...
DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation
The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...
Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development
Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...
Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer
Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...